Classic congenital adrenal hyperplasia, more commonly called classic CAH, is when there is an enzyme missing in the adrenal gland, which causes the body to have the inability to make enough cortisol.

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone ...

The first CRFR1 antagonist (crinecerfont) to be used for the treatment of congenital adrenal hyperplasia recently received FDA approval. This Clinical Outlook discusses the latest phase III ...

For the first time ever, the FDA has approved a treatment specifically for people with classic congenital adrenal hyperplasia (CAH ... to crack the code of the disease they’re trying to ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for the rare disorder that works by directly targeting the underlying ...

HBM Alpha Therapeutics has signed a collaboration and licensing agreement, granting an unnamed business partner exclusive ...

Adults with primary aldosteronism had improvements in disease severity after undergoing ... factor type 1 receptor to treat congenital adrenal hyperplasia, according to a press release.